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-7 through -2, before 200 cGy TBI. Unmodified G-CSF-mobi- 
lized peripheral blood stem cells (PBSC) from DLA-haploidenti- 
cal donors were infused followed by iunnunosuppression with 
MMF (5-I0 mg/kg BID SQ for 28-101 days) and CSP (3- 
15mg/kg BID PO for 102 days). Two dogs received additional 
weekly methotrexate (0.4 mg/kg IV from days 42 through 105) 
and 2 dogs received escalating dose of donor lymphocyte infusions 
(DLI) fi'om their donors. Results: All dogs achieved prompt ini- 
tial engraftment with donor chimerism of PBMC ranging from 5- 
90% (median; 60%) 3 weeks after transplant. However, of 2l dogs 
evaluable for engraftment, 15 (71%) rejected their donor grafts 
after discontinnation r dose-reduction f MMF/CSP (5-16 weeks 
after transplant). Graft rejections occurred later in dogs given pro- 
longed immnnosuppression when compared to those treated with 
short courses (median time to rejection; 13.5 weeks vs. 7 weeks). 
Sustained allografts for more than 20 weeks were observed in 6 
dogs (29% of evaluable dogs). One of the 2 dogs given DLI 
achieved conversion to full donor chimerism after the third DLI 
dose (CD3+ cells infilsed; lxl07/kg) with subsequent graft versus- 
host disease requiring therapy. Conclusion: Initial engraftment of 
DLA-haploidentical PBSC can be achieved by anti-CD44 therapy 
and 200 cGy TBI with MMF/CSP. In some cases, sustained allo- 
grafts were achieved, however, half the dogs rejected their donor 
grafts after discontinuation or dose-reduction of MMF/CSP. 
Modification to current protocols will be needed to consistently 
achieve long-lasting engraftment. 
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UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) FROM HLA 
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We and others have demonstrated that UCB has been success- 
fully used as an alternative source of hematopoietic stem cells for 
both malignant and non-malignant diseases (Cairo et al, Blood 
90:4665, 1997). We analyzed the results of 31 UCBT in 29 pts 
between 1997-2002. Age: median 9 (0.7-20) yrs; 17M:I2F; and 
reed wt 2i kg" (range 8-95). Dx: 23 malignant (9 ALL, 4 AML, 1 
CML, 3 EID, 3 NHL, 2 NBL, 1 HLH), and 6 non-malignant (1 
B-Thal, 1 WAS, 1 FEL, 1 SAA, 1 FA, 1 Krabbe dis). HLA typing 
was done by serology class i (A & B) and high resolution DNA 
typing class II (DRB1). Donor sources: 3 (6/6), 7 (5/6), 21 (4/6). 
Conditioning: TBI-based (15), chemotherapy-based (6) and 
reduced intensity chemotherapy (10). 28 received ATG/MoAb. 
GVHD prophylaxis: MNIF/FK506 (20), CsA+steroids+~VINiF (7) 
or CsA+Mtx (4). UCB median TNC 4.9x107/kg (1.1-16.9), medi- 
an CD34+ 2.8x105/kg (0.2-9.9). 84% smwived more than 30 days. 
Of those surviving 30 d: med time to ANC >0.5x10~TL 24 d (1- 
79); reed time to PLT >20xl0V/L 31 d (1 206); 81% had ANC 
>0.5xI0')/L by day +60; 67% had PLT ->20x10'TL by day +180. 
There was a 10% primary graft fiailure. 23 were evaluable for 
A/CGVHD. 35% developed _>grade II AGVHD, reed 29d (7-53), 
22% developed ->grade III AGVItD; 5.9% developed extensive 
CGVHD. The estimated 1-yr OS is 42%. 14 remain alive and dis 
free 1-62 mo. Factors predicting positive outcome by univariate 
analysis: number of CD34+ cells/kg (p=0.045), number of 
TNC/kg (p=0.072), non-TBI conditioning (p=0.027), standard 
risk vs poor risk (p-0.036), and sex (F) (p=0.015). By multivariate 
analysis: number of CD34+ cells/kg (p=0.035), non-TBI condi- 
tioning (p=0.026) and sex (F) (p=0.031). Patients who survived 
received more CD34+ eells/kg (3.I vs 2x105, p=0.045) and more 
TNC/kg (5.1 vs 3x107, p=0.11). HLA disparity did not predict for 
OS. In summary, this experience with HLA disparate UCBT con- 
tinues to demonstrate a very low incidence of ->grade II AGVHD 
and extensive CGVHD, and more importantly, in a multivariate 
analysis, non-TBI conditioning and higher CD34/kg dose are the 
most important predictors for significantly improved survival. 
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OPTIMAL SELECTIVE TYPING STRATEGIES FOR DONOR REGISTRIES 
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Ge~wla W. 
A reasonable measure for the quality of the composition of a 
registry is the fraction of patients finding at least one matching 
donor on the first search of the registry. This indicates to 
which extent he phenotype spectrum of population is covered 
by the registry. For a population Hardy-Weinberg Equilibri- 
um, this "population coverage" can be estimated using the size 
of the registry and the HLA haplotype frequencies. Due to lim- 
ited funds, many registries contain a majority of donors which 
are only typed for HLA-A and -B. We have designed an algo- 
rithm to select such donors for HLA-DRBl-typing by their 
HLA-A, B-phenotype so that after a defined number of typings 
performed the expected population coverage is maximized. 
This algorithm uses HLA haplotype frequencies to estimate 
absolute HLA-A, B, DR-phenotype frequencies as well as con- 
ditional distributions of HLA-DRB1 subtypes for each HLA-A, 
B-phenotype. Then, taking into account the current registry 
composition, a sequence of donors to be typed for IILA-DRB1 
can be established optimizing the chance of a patient o have an 
HLA-A, B, DRBl-matching donor instantly. A computer sinm- 
lation of this process revealed that our strategy can save initially 
up to 60% of typing costs over a random selection of HLA 
types and that the gain in efficiency will then remain between 
15% and 25% until over 80% of the donors are fully typed. 
Since HLA typing costs are the largest burden on the budget of 
most registries this strategy can have a substantial economic 
impact. 
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Unrelated UCBT have been used as an alternative source of 
stem cells in the treatment ofnon-malignant and malignant disor- 
ders. From 7/6/95 to 7/11/02 seventy-one children underwent 
UCBT at Childrens Memorial Hospital. Fifty three had malig- 
nant disorders and 18 non-malignant. Thirty-eight were male and 
33 females with a mean age at transplant of 6.5 years (range 0.6- 
20.5 years). The ablation regimen consisted of fFBI 1200cGy in 
150cGy fractions (days -8, -7, -6, -5), cyclophosphamide 60
mg/kg/day (days -4, -3, -2); and for patients with malignant disor- 
ders VP-16 was given at a lO00mg/m2/day as a CI (day 4). The 
GVHD prophylaxis consisted of CSA 5 mg/kg/day as a 24 hr CI, 
MTX 15/m2 on day 1 and 10rag/m2 on day +3 and +6 plus ATG 
40 lng/kg/day on days +l, +3, +5, and +7. Selection of UCB was 
made based on the HLA typing and total cell dose. HLA typing 
was originally performed by serological methods for class I and by 
DNA based methods for DRB1. Since March 2000, HLA typing 
has been performed using DNA-based typing methods only. 
Eighteen patients were HLA-A, B, and DR typed serologically 
only, and the degree of matching was 6/6 (n= I), 5/6 (n= 6), 4/6 
(n= 10) and 3/6 (n= 1). Fifty-three patients were DNA-typed, 
HLA-A and B at the group level and DRBI at the allele level. In 
these patients the degree of matching was: 6/6 (n=4), 5/6 (n=14), 
4/6 (n=33), and 3/6 (n=2). The total cell dose infused was a mean 
0.63 xl08/kg, (range 0.11- 1.92 xl08/kg). The time to achieve 
ANC> 500/UI were 27.4 (range 14-58 days) was achieved in 58 
pts. And for sustained platelets >20/UI 47days, (range 10-128 
days). And were achieved in 47pts. From the 71 patients, 35 died 
from infection (n= 11), relapse (n= 8), transplant related toxicity 
(n= 3), PTLD (n= 1), chronic GVHD (n= 1), and others (n- 9) 
from these 7 did not engraft. Forty seven patients developed 
AGVIID (grade I/]I n= 32 or grade III/IV n= 15), in 40 of them, 
AGVHD resolved with immune-suppressive th rapy. CGVHD in 
10 patients (resolved in 7, persisted in 3). The actuarial 3-year 
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